Identification of a proliferator‑activated receptor-γ antagonist for the treatment of type 2 diabetes mellitus

Wang,Ren; Dai,Lihua; Chen,Jinjin

doi:10.3892/etm.2014.2096

Identification of a proliferator‑activated receptor-γ antagonist for the treatment of type 2 diabetes mellitus

Authors:
- Ren Wang
- Lihua Dai
- Jinjin Chen
View Affiliations

Affiliations: Department of Ultrasonography, Shanghai Sixth People's Hospital, Affiliated to Shanghai Jiao Tong University, Shanghai 200233, P.R. China, Department of Emergency, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China, Department of Child Health Care, Shanghai Children's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200040, P.R. China
Published online on: December 1, 2014 https://doi.org/10.3892/etm.2014.2096
Pages: 446-450

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, a novel antagonist of the peroxisome proliferator‑activated receptor‑γ (PPARγ) was screened and identified, and a cell‑based evaluation of the biological activity of this PPARγ antagonist was conducted. The aim of the study was to produce results that may provide a foundation for the development of a novel compound in the treatment of type 2 diabetes mellitus. Since obesity is the main cause of insulin resistance and type 2 diabetes, identifying a new reagent that is able to inhibit adipocyte differentiation and lipid accumulation is a feasible method of developing novel anti-diabetes drugs. The PPARγ antagonist was screened using a mammalian one‑hybrid system and transcriptional activation. The effects of the compound on adipocyte differentiation were investigated by staining the preadipocytes with Oil Red O. In addition, the effects of the compound on the expression levels of genes associated with lipid metabolism were detected using quantitative polymerase chain reaction on differentiated mature 3T3‑L1 adipocytes. As a PPARγ antagonist, N-((1H-benzo[d]imidazol-2-yl)methyl) aniline (Compound Q) was shown to depress the transcriptional activity and coactivator recruitment of PPARγ, as well as preadipocyte differentiation, in a concentration‑dependent manner. The compound was also shown to decrease the expression levels of genes associated with PPARγ‑regulated lipid metabolism. In conclusion, the compound screening platform was demonstrated to be valid, and the present study identified a novel PPARγ antagonist that was shown to effectively reduce the rate of adipocyte differentiation and the expression of genes associated with lipid metabolism.

View Figures

View References

1	Samuel VT and Shulman GI: Mechanisms for insulin resistance: common threads and missing links. Cell. 148:852–871. 2012. View Article : Google Scholar : PubMed/NCBI
2	Kahn SE, Hull RL and Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 444:840–846. 2006. View Article : Google Scholar : PubMed/NCBI
3	Kumar PR, Bhansali A, Ravikiran M, et al: Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study. J Clin Endocrinol Metab. 95:2832–2835. 2010. View Article : Google Scholar : PubMed/NCBI
4	Halperin F and Goldfine AB: Metabolic surgery for type 2 diabetes: efficacy and risks. Curr Opin Endocrinol Diabetes Obes. 20:98–105. 2013. View Article : Google Scholar : PubMed/NCBI
5	Houseknecht KL, Cole BM and Steele PJ: Peroxisome proliferator-activated receptor gamma (PPAR gamma) and its ligands: a review. Domest Anim Endocrinol. 22:1–23. 2002. View Article : Google Scholar : PubMed/NCBI
6	Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N and DeFronzo RA: Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia. 50:1723–1731. 2007. View Article : Google Scholar : PubMed/NCBI
7	Sharma AM and Staels B: Review: Peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab. 92:386–395. 2007. View Article : Google Scholar
8	Shearer BG and Billin AN: The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta. 1771:1082–1093. 2007. View Article : Google Scholar : PubMed/NCBI
9	Clement K, Hercberg S, Passinge B, et al: The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord. 24:391–393. 2000. View Article : Google Scholar : PubMed/NCBI
10	Kadowaki T: PPAR gamma agonist and antagonist. Nihon Yakurigaku Zasshi. 118:321–326. 2001.(In Japanese). View Article : Google Scholar : PubMed/NCBI
11	Zinman B: PPAR gamma agonists in type 2 diabetes: how far have we come in ‘preventing the inevitable’? A review of the metabolic effects of rosiglitazone. Diabetes Obes Metab. 3(Suppl 1): S34–S43. 2001. View Article : Google Scholar
12	Wojtowicz AK, Szychowski KA and Kajta M: PPAR-γ agonist GW1929 but not antagonist GW9662 reduces TBBPA-induced neurotoxicity in primary neocortical cells. Neurotox Res. 25:311–322. 2014. View Article : Google Scholar
13	de Boer RA, Martens FM, Kuipers I, Boomsma F and Visseren FL: The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus. J Hum Hypertens. 24:74–76. 2010. View Article : Google Scholar
14	Chawla A, Schwarz EJ, Dimaculangan DD and Lazar MA: Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 135:798–800. 1994.PubMed/NCBI
15	Huang C, Zhang Y, Gong Z, Sheng X, Li Z, Zhang W and Qin Y: Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway. Biochem Biophys Res Commun. 348:571–578. 2006. View Article : Google Scholar : PubMed/NCBI
16	Sheu W, Jeng CY, Fuh M, Chen YD and Reaven GM: Resistance to insulin-mediated glucose disposal in patients with noninsulin-dependent diabetes mellitus in the absence of obesity or microalbuminuria - a Clinical Research Center study. J Clin Endocrinol Metab. 81:1156–1159. 1996.PubMed/NCBI
17	Chatterjee PK: Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation. Br J Pharmacol. 160:1889–1891. 2010. View Article : Google Scholar : PubMed/NCBI
18	Khan A, Safdar M, Ali Khan MM, Khattak KN and Anderson RA: Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 26:3215–3218. 2003. View Article : Google Scholar : PubMed/NCBI
19	Bøg-Hansen E, Lindblad U, Rånstam J, Melander A and Rastam L: Impaired glucose metabolism and obesity in Swedish patients with borderline isolated systolic hypertension: Skaraborg Hypertension and Diabetes Project. Diabetes Obes Metab. 3:25–31. 2001. View Article : Google Scholar : PubMed/NCBI
20	Hanas R and Ludvigsson J: Side effects and indwelling times of subcutaneous catheters for insulin injections: a new device for injecting insulin with a minimum of pain in the treatment of insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 10:73–83. 1990. View Article : Google Scholar : PubMed/NCBI
21	Chiang CK, Ho TI, Peng YS, et al: Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care. 30:3–7. 2007. View Article : Google Scholar
22	Zhang F, Lavan BE and Gregoire FM: Selective modulators of PPAR-gamma activity: Molecular aspects related to obesity and side-effects. PPAR Res. 2007:326962007. View Article : Google Scholar : PubMed/NCBI
23	Evans RM, Barish GD and Wang YX: PPARs and the complex journey to obesity. Nat Med. 10:355–361. 2004. View Article : Google Scholar : PubMed/NCBI